Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Oramed Pharmaceuticals (ORMP) Research & Development (2022 - 2025)

Oramed Pharmaceuticals' Research & Development history spans 4 years, with the latest figure at $1.5 million for Q4 2025.

  • For Q4 2025, Research & Development changed N/A year-over-year to $1.5 million; the TTM value through Dec 2025 reached $5.9 million, changed N/A, while the annual FY2025 figure was $6.4 million, 0.9% up from the prior year.
  • Research & Development reached $1.5 million in Q4 2025 per ORMP's latest filing, up from $1.2 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $9.2 million in Q2 2022 to a low of $957000.0 in Q3 2023.
  • Average Research & Development over 4 years is $3.3 million, with a median of $1.8 million recorded in 2023.
  • Peak YoY movement for Research & Development: crashed 82.1% in 2023, then surged 134.27% in 2024.
  • A 4-year view of Research & Development shows it stood at $9.0 million in 2022, then plummeted by 80.46% to $1.8 million in 2023, then grew by 26.95% to $2.2 million in 2024, then plummeted by 32.29% to $1.5 million in 2025.
  • Per Business Quant, the three most recent readings for ORMP's Research & Development are $1.5 million (Q4 2025), $1.2 million (Q3 2025), and $1.0 million (Q2 2025).